Evidence map›Paper›PMID 25590535›Full record

ArticleMolecular pharmaceutics2015

Structural characterization and in vivo evaluation of β-Hairpin peptidomimetics as specific CXCR4 imaging agents.

Wojciech G Lesniak, Emilia Sikorska, Hassan Shallal, Babak Behnam Azad, Ala Lisok, Mrudula Pullambhatla, Martin G Pomper, Sridhar Nimmagadda

Abstract read
In one paragraph

Article in Molecular pharmaceutics, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.9field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. In vivo Evaluation of an Engineered Cyclotide as Specific CXCR4 Imaging Reagent.Chemistry (Weinheim an der Bergstrasse, Germany) · 2017
    Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 2 countries.

Wojciech G LesniakRussell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University , Baltimore, Maryland 21287, United States.
Emilia Sikorska
Hassan Shallal
Babak Behnam Azad
Ala Lisok
Mrudula Pullambhatla
Martin G Pomper
Sridhar Nimmagadda
Johns Hopkins University · USUniversity of Gdańsk · PL

Funding

Translational Research Central ServicesP30CA006973 · NCI · JOHNS HOPKINS UNIVERSITY · PI Rosalie Wollett · 1985 to 2026
$208.6M
Theranostic Imaging of Metastatic Prostate CancerP50CA103175 · NCI · JOHNS HOPKINS UNIVERSITY · PI BARKER, PETER B · 2003 to 2015
$17.9M
Imaging and targeting metastatic diseaseR01CA166131 · NCI · JOHNS HOPKINS UNIVERSITY · PI NIMMAGADDA, SRIDHAR · 2012 to 2016
$1.6M
NCI NIH HHS P30 CA006973NCI NIH HHS P50 CA103175NCI NIH HHS P50CA103175NCI NIH HHS R01 CA166131
6 · The paper itself

Abstract

The CXCR4 chemokine receptor is integral to several biological functions and plays a pivotal role in the pathophysiology of many diseases. As such, CXCR4 is an enticing target for the development of imaging and therapeutic agents. Here we report the evaluation of the POL3026 peptidomimetic template for the development of imaging agents that target CXCR4. Structural and conformational analyses of POL3026 and two of its conjugates, DOTA (POL-D) and PEG12-DOTA (POL-PD), by circular dichroism, two-dimensional NMR spectroscopy and molecular dynamics calculations are reported. In silico observations were experimentally verified with in vitro affinity assays and rationalized using crystal structure-based molecular modeling studies. [(111)In]-labeled DOTA conjugates were assessed in vivo for target specificity in CXCR4 expressing subcutaneous U87 tumors (U87-stb-CXCR4) through single photon emission computed tomography (SPECT/CT) imaging and biodistribution studies. In silico and in vitro studies show that POL3026 and its conjugates demonstrate similar interactions with different micelles that mimic cellular membrane and that the ε-NH2 of lysine(7) is critical to maintain high affinity to CXCR4. Modification of this group with DOTA or PEG12-DOTA led to the decrease of IC50 value from 0.087 nM for POL3026 to 0.47 nM and 1.42 nM for POL-D and POL-PD, respectively. In spite of the decreased affinity toward CXCR4, [(111)In]POL-D and [(111)In]POL-PD demonstrated high and significant uptake in U87-stb-CXCR4 tumors compared to the control U87 tumors at 90 min and 24 h post injection. Uptake in U87-stb-CXCR4 tumors could be blocked by unlabeled POL3026, indicating specificity of the agents in vivo. These results suggest POL3026 as a promising template to develop new imaging agents that target CXCR4.

Indexed as

AnimalsBinding, CompetitiveBiopharmaceuticsCell Line, TumorFemaleGlioblastomaHeterocyclic Compounds, 1-RingHeterograftsHumansMiceMice, Inbred NODMice, SCIDModels, MolecularMolecular Dynamics SimulationMolecular StructureNuclear Magnetic Resonance, Biomolecular1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acidCXCR4 protein, humanHeterocyclic Compounds, 1-RingPeptides, CyclicPeptidomimeticsPOL3026 peptideReceptors, CXCR4chemokinechemokine receptorCXCR4molecular imagingSPECT/CT

Identifiers

PMID25590535
PMCPMC4612581
OpenAlexW2325132427

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.